Tao An

Tao An

Auto-generated profile, based on publicly available information

Tao An

Department of Cardiology, Fuwai Hospital, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2018 in Cancer Communications
Verified
Journal Article
Open access
PDF file
BLBinliang Liu
Binliang Liu
TATao An
Tao An
MLMeiying Li
Meiying Li
ZYZongbi Yi
Zongbi Yi
CLChunxiao Li
Chunxiao Li
YZYixin Zeng
Yixin Zeng
Background: An increasing number of cancer patients die of cardiovascular diseases. The cardiotoxicity of chemotherapy is particularly important in triple‐negative breast cancer (TNBC) with limited therapeutic options. Cardiac autophagy is an important mechanism of cardiotoxicity. This research was aimed to investigate the cardiotoxicity of chemotherapy in TNBC, screen the susceptible population, and determine the relationship between cardiotoxicity and autophagy‐related polymorphisms. Methods: From a total of 2450 stage I‐III TNBC patients, 147 met the inclusion criteria and finally recruited. Electrocardiography (ECG) was performed before most chemotherapy cycles, and echocardiography (UCG) was performed according to clinical needs. All ECG and UCG records were re‐interpreted by cardiologists at the National Center for Cardiovascular Disease, Fuwai Hospital. According to the National Center for Biotechnology Information and the Catalog of Somatic Mutations in Cancer database, we selected 25 single nucleotide polymorphisms (SNPs) related to autophagy and genotyped the 147 TNBC patients. Paired‐sample T tests, Chi squared tests, and logistic regression models were employed for the analysis. Results: Only 46 (31.3%) patients had normal ECG records after every chemotherapy cycle. Among the 16 patients who underwent UCG, 2 (12.5%) had a reversible decrease of left ventricular ejection fraction. The use of anthracyclines and excessive alcohol consumption were risk factors of ECG abnormalities. With the continuation of chemotherapy, heart rate gradually increased. Anthracyclines were associated with QRS duration abnormalities ( P = 0.043). After genotyping for 25 autophagy‐related SNPs, we found that the G allele of autophagy‐related 13 ( ATG13 ) rs10838611 was significantly associated with ECG abnormalities (odds ratio = 2.258, 95% confidence interval = 1.318–3.869; P = 0.003). Conclusion: ECG abnormalities caused by chemotherapy are common in the real world. Autophagy‐related SNPs are associated with chemotherapy‐induced cardiotoxicity, thereby providing new evidence for autophagy as a cause of chemotherapy‐induced cardiac damage.

26 July 2023 in Current Cardiology Reports
Verified
Journal Article
Open access
PDF file
YZYiqi Zhao
Yiqi Zhao
HJHao Jia
Hao Jia
XHXiumeng Hua
Xiumeng Hua
TATao An
Tao An
JSJiangping Song
Jiangping Song
Purpose of Review: The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health. Recent Findings: Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD. Summary: This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.

6 January 2021 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
MGMinglian Gong
Minglian Gong
HPHongyu Peng
Hongyu Peng
ZWZheng Wu
Zheng Wu
WLWenzheng Li
Wenzheng Li
YLYuan Lv
Yuan Lv
JLJinghua Liu
Jinghua Liu

15 December 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JZJing Zhao
Jing Zhao
RTRui Tian
Rui Tian
TATao An
Tao An
JXJing Xu
Jing Xu
TCTingting Cui
Tingting Cui
ZXZuojun Xu
Zuojun Xu

10 March 2026 in Asian Heart Journal
Verified
Journal Article
Open access
HWHao-Yu Wang
Hao-Yu Wang
SYSheng Yuan
Sheng Yuan
XYXin Yi
Xin Yi
GGGuofeng Gao
Guofeng Gao
RZRui Zhang
Rui Zhang
KDKe-Fei Dou
Ke-Fei Dou
Objectives: The transition from short dual antiplatelet therapy (DAPT) to P2Y 12 inhibitor monotherapy has recently gained popularity as a strategy to reduce aspirin-related bleeding while preserving the antithrombotic benefit of DAPT. However, the safety and efficacy of P2Y 12 inhibitor monotherapy after short-term DAPT in patients who received complex percutaneous coronary intervention (PCI) remains uncertain. Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science were searched to identify randomized controlled trials published in any language between January 1980 and June 2023. Only peer-reviewed articles and randomized controlled trials were included. The primary efficacy and safety endpoints were major adverse cardiovascular events and major bleeding. We divided antiplatelet strategies into three categories based on previous clinical trials: P2Y 12 inhibitor monotherapy after 1 or 3 months DAPT, aspirin monotherapy after 3 or 6 months DAPT, and aspirin monotherapy after long-term (≥12 months) DAPT. The network meta-analysis was performed by the frequentist approach (PROSPERO-ID CRD42020192256). Results: Nine studies involving 16,201 patients with complex PCI were included. Within 1 year after complex PCI, the pooled results showed that compared with long-term DAPT, 1 or 3 months DAPT followed by P2Y 12 inhibitor monotherapy could significantly reduce the risk of primary efficacy endpoint (hazard ratio [HR], 0.67; 95% confidence interval [CI]: 0.52–0.87) as well as the risk of all-cause mortality (HR, 0.55; 95% CI, 0.37–0.81), target vessel revascularization (HR, 0.60; 95% CI, 0.45–0.79), and any bleeding events (HR, 0.52; 95% CI, 0.38–0.73). The indirect comparison revealed that P2Y 12 inhibitor monotherapy was correlated with a lower risk of major adverse cardiovascular events (HR, 0.44; 95% CI, 0.27–0.71), myocardial infarction (HR, 0.50; 95% CI, 0.28–0.90), and target vessel revascularization (HR, 0.61; 95% CI, 0.37–0.98) at 12 months compared with aspirin monotherapy after 3 or 6 months DAPT. Beyond 12 months, there were no significant differences in terms of major adverse cardiovascular events among these three antiplatelet treatments, while major bleeding (HR, 0.37; 95% CI, 0.14–0.94) resulted significantly lower, adopting an aspirin monotherapy strategy compared with prolonged DAPT. Conclusion: For patients with complex PCI, early discontinuation of DAPT to P2Y 12 inhibitor monotherapy might be a safer and equally effective strategy compared with aspirin monotherapy after 3 or 6 months or long-term DAPT.